PhRMA and EFPIA commissioned report on HTAs finds concerns over speed and transparency
The Pharmaceutical Research and Manufacturers of America (PhRMA) has announced the release of a report at the Health Technology Assessment International (HTAi) annual meeting in Washington DC, USA.
A Comparative Analysis of the Role and Impact of Health Technology Assessment, commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and PhRMA, updates a previous study conducted in 2011. The study covers a range of countries globally, and adds new markets compared to its 2011 edition, including emerging markets with formal conventional HTA systems in place. With individual country cards, it compares 16 conventional HTA systems against a set of best practice principles regarding scope and prioritization, methodology, process and impact of HTA.
Concerns about clarity
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze